Art. -Nr.: HY-B0896

Triacetin

(Synonyms: Glyceryl triacetate; 1,2,3-Triacetoxypropane)

Kundenbewertung

Based on 1 Customer Validation

Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 102-76-1
Formel: C₉H₁₄O₆
Molecular Weight:218.20

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Triacetin Chemical Structure

CAS. Nr.: 102-76-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Human Endogenous Metabolite

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

In Vitro

Triacetin (0.25%, 24 h) induces growth arrest of HOG, Hs683, U87, U251, OG33, OG35 GBM9, GBM12, GBM34, GBM2, GBM8 and GBM44 cells in vitro^[1].
Triacetin (25 mM, 24 h) causes effective inhibition on the U87MG (human malignant glioma) cell viability^[2].
Triacetin (12.5-25 mM, 24 h) induces clear G2/M cell-cycle arrest in U87MG cells.^[2].
Triacetin (12.5 mM) induces apoptosis in GBM cancer cells^[2].
Triacetin (25 mM, 24 h) decreases the class I and class II HDAC (histone deacetylase) mRNA expression in U87MG cells^[2].
Triacetin (12.5 mM, 24 h) inhibits HDAC-8 activity in U87MG cells^[2].
Triacetin (12.5 mM, 24 h) activates the mTOR complexes downstream genes which play an important role in cancer cell metabolism such as S6K1, mSIN1, Protor 2, and PKCα^[2].
Triacetin (12.5 mM, 24 h) shows an increased tumor suppressor miRs that can inhibit growth, proliferation, invasion, migration, and angiogenesis in U87MG cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

Established glioma cell lines and primary tumor-derived GSCs.
Concentration:

0.25%
Incubation Time:

24 h
Result:

Induced G0 growth arrest of all glioma cells, except U87, U251 and GBM (glioblastoma) 8 GSCs, without affecting Oli-Neu OPCs (oligodendrocyte progenitor cell line) or astrocytes and promoted NSC (neural stem cells) expansion.
The growth reduction of established glioma cell lines and primary tumor-derived GSCs in vitro is not due to the promotion of differentiation.

Cell Cycle Analysis^[2]

Cell Line:

U87 MG cells
Concentration:

12.5, 25 mM
Incubation Time:

24 h
Result:

Induced 12% and 25% of sub-G1 cells and 60% and 79% of G2/M cells.

Apoptosis Analysis^[2]

Cell Line:

GBM cancer cells
Concentration:

12.5 mM
Incubation Time:

24 h
Result:

Increased caspase-3 activity in treated GBM cancer cells.

RT-PCR^[2]

Cell Line:

U87MG cells
Concentration:

25 mM
Incubation Time:

24 h
Result:

Decreased the classI and class II HDAC (histone deacetylase) mRNA expression.
Increased expression of S6K1, mSIN1, Protor 2, and PKCα.
Increased expression of miR-15b, miR-92, miR-101, miR-155, miR-199, miR-200, miR-223, and slight increase in expression in miR-16 and miR-17.

In Vivo

Triacetin (5.0 g/kg with 10% v/v oral-sweet SF, p.o., daily, 14 days) enhances TMZ (Temozolomide) (HY-17364) chemotherapeutic efficacy in mice engrafted with oligodendroglioma-derived GSCs^[1].
Triacetin (5.0 g/kg with 10% v/v Ora-Sweet SF, p.o., daily, 40days) alone increases survival of mice orthotopically engrafted with GBM-derived GSCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult (8 week, 24 - 28g) male athymic mice orthotopically engrafted with oligodendroglioma-derived GSC cells ^[1].
Dosage:

5.0 g/kg with 10% v/v oral-sweet SF
Administration:

p.o., daily, 14 days
Result:

Significantly reduced tumor bioluminescence and increased survival but did not reduce end-point tumor volume with treatment of TMZ (Temozolomide) (HY-17364).

Animal Model:

Adult (8 week, 24 - 28g) male athymic mice orthotopically engrafted with GBM-derived GSC cells^[1].
Dosage:

5.0 g/kg with 10% v/v oral-sweet SF
Administration:

p.o., daily, 40 days
Result:

Alone did not alter blood glucose, bioluminescence, or end-point tumor volume; however, increased survival.
Significantly increased survival with treatment of TMZ, with two of eight mice never redeveloping measurable flux or displaying histological signs of tumor at study termination.

Chemical Information

CAS. Nr. 102-76-1
Appearance Liquid (Density: 1.16 g/cm³)
Molecular Weight 218.20
Formel C₉H₁₄O₆
Color Colorless to light yellow
SMILES

CC(OCC(OC(C)=O)COC(C)=O)=O
Synonyms

Glyceryl triacetate; 1,2,3-Triacetoxypropane
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 200 mg/mL (916.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.5830 mL

22.9148 mL

45.8295 mL

5 mM

0.9166 mL

4.5830 mL

9.1659 mL

10 mM

0.4583 mL

2.2915 mL

4.5830 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (22.91 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (22.91 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 5 mg/mL (22.91 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tsen AR, et al. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Int J Cancer. 2014 Mar 15;134(6):1300-10. [Content Brief]

[2]. Mekala JR, et al. N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro. Life Sci. 2021 Dec 1;286:120024. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.5830 mL	22.9148 mL	45.8295 mL	114.5738 mL
	5 mM	0.9166 mL	4.5830 mL	9.1659 mL	22.9148 mL
	10 mM	0.4583 mL	2.2915 mL	4.5830 mL	11.4574 mL
	15 mM	0.3055 mL	1.5277 mL	3.0553 mL	7.6383 mL
	20 mM	0.2291 mL	1.1457 mL	2.2915 mL	5.7287 mL
	25 mM	0.1833 mL	0.9166 mL	1.8332 mL	4.5830 mL
	30 mM	0.1528 mL	0.7638 mL	1.5277 mL	3.8191 mL
	40 mM	0.1146 mL	0.5729 mL	1.1457 mL	2.8643 mL
	50 mM	0.0917 mL	0.4583 mL	0.9166 mL	2.2915 mL
	60 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9096 mL
	80 mM	0.0573 mL	0.2864 mL	0.5729 mL	1.4322 mL
	100 mM	0.0458 mL	0.2291 mL	0.4583 mL	1.1457 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Triacetin

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Antifungal Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Food Additive Library

Food-Sourced Compound Library

Inactive Ingredient Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Natural Product Diversity Scaffold Library

Environmental Pollutant Compound Library

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Triacetin Related Classifications

HY-B0896 Related Classifications